The company expects that the addition of its AR-713 monoclonal antibody will result in a self-administered, inhalable dual-antibody cocktail that will provide broad coverage of all known high-risk COVID-19 strains. A phase II/II/III clinical trial is expected to begin in the second half of 2021.

Preclinical development services are being supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) according to Aridis.

FDA releases new guidance for developers of COVID-19 products
The U.S. Food and Drug Administration (FDA) has released new guidance for developers of products for COVID-19 vaccines, therapies, and tests with a particular...

Biohaven's antiviral antibody conjugate is effective in vitro
Biohaven Pharmaceutical's hyperimmune globulin mimic, developed on its proprietary multimodal antibody therapy enhancer platform, has demonstrated functional...

TFF, U.S. Army achieve milestone in freeze-dried biodefense therapies
TFF Pharmaceuticals, in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases, has announced positive preclinical in vitro...

Regeneron publishes data supporting Ab cocktail as passive COVID-19 vaccine
Regeneron said that interim data from its ongoing phase III clinical trial supports the use of its Regen-CoV antibody (Ab) cocktail as a passive vaccine...

Aridis touts positive preclinical results for COVID-19 mAb treatment
Anti-infective therapies firm Aridis Pharmaceuticals has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel...